MARKET WIRESeeking Alpha • 1d ago
PepGen: Maintaining 'Hold,' PGN-EDODM1 Data Is A Major Inflection PointSeeking Alpha report covering PepGen Inc. (PEPG) market action, institutional positioning, and fundamental catalysts.
Why PEPG Stock slipped -0.42% Today — RQD Quant Desk Flash
$2.35 -0.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.34
PepGen Inc. (PEPG) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $163.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PEPG Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PEPG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, PepGen Inc. (NASDAQ: PEPG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $2.35 (-0.42% 1D, market cap $163.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PEPG ranks #598 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PEPG compare to VRXA and ADAG in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PEPG carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VRXA (Veraxa Biotech AG) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $161.2M) and ADAG (Adagene Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $165.8M). Among the 5-stock peer group, PEPG leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PEPG?
▼
Per PEPG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835597), PepGen Inc. generated $262.1M in revenue (-4.2% YoY), -$89.7M in net income, and -$81.9M in free cash flow against $173.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.34 (-0.27%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PEPG)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY PEPG SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)
FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 42 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$2.50+14.8% Next Q
43
Q2 (-2Q)Grade D$2.87-9.4% Next Q
40
Q3 (-1Q)Grade E$2.60-9.6% Next Q
38
CurrentGrade D-$2.35-8.5% Hist 90D α
35
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PEPG Turnaround Squeeze
While PEPG currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.72) and Max Pain ($2.47) forces dealer call-delta covering toward $8.19.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PEPG• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PEPG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PEPG Stock slipped -0.42% Today — RQD Quant Desk Flash
PepGen Inc. (PEPG) slipped -0.42% to $2.35, trading at 16% of its 52-week range ($1.31 – $7.8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 16% of its 52-week range ($1.31 – $7.8) with RSI-14 at 42 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.35 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live PEPG Headlines & Catalysts
MARKET WIRETradingView • 1d ago
PepGen Inc. Estimates – NASDAQ:PEPGTradingView report covering PepGen Inc. (PEPG) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 1d ago
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and PepGen Inc. (PEPG)The Globe and Mail report covering PepGen Inc. (PEPG) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 89d ago
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsBOSTON, August 06, 2026--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
MARKET WIREYahoo Finance • 89d ago
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB ReviewBOSTON, August 06, 2026--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
MARKET WIREYahoo Finance • 170d ago
Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?PepGen Inc. (NASDAQ:PEPG) is one of the best NASDAQ stocks under $5 to buy right now. On May 12, PepGen reported Q1 2026 financial results, recording a net loss of $17.8 million, or $0.26 per share, compared to a net los
MARKET WIREYahoo Finance • 217d ago
PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort UnderwayPepGen (NASDAQ:PEPG) reported top-line results from the lowest-dose cohort of its Phase II FREEDOM2 multiple ascending dose (MAD) study evaluating PGN-EDO-DM1 in myotonic dystrophy type 1 (DM1), highlighting what managem
CATALYSTYahoo Finance • 167d ago
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerPepGen (PEPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend
CATALYSTYahoo Finance • 174d ago
PepGen (PEPG) Upgraded to Buy: Here's What You Should KnowPepGen (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
RISK WATCHYahoo Finance • 175d ago
AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical OfficerBrings more than 20 years of neurology, clinical development, and translational experience as AstronauTx prepares to advance its lead programmes into clinical developmentAstronauTx also appoints Deb Gouveia as Vice Presi
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PEPG)
- ✓Walkthrough of PEPG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PEPG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.56%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.41H $2.41L $2.35C $2.35VOL 1.13M
RES: $4.22SUP: $2.24SMA50: $2.72SMA200: $3.01
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PEPG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -4.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on PEPG today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PEPG. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PEPG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PEPG)
Health Care Rank #598 of 1015
⚔️ VRXA vs PEPG Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PEPG vs. VRXA, ADAG, ANTX, ORMP)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, PepGen Inc. (PEPG) ranks #598 by composite RQD confidence (35/100, grade D-) and #597 by equity capitalization ($163.5M). Within this direct 5-issuer industry benchmark cohort, PEPG leads on earnings valuation at N/A trailing P/E, while ORMP leads on capital efficiency and profitability with -7.8% ROIC and 0.7% gross margin. VRXA currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with PEPG at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PEPG
ACTIVE
PepGen Inc. | D- | 35/100 | — | — | -35.0% | -0.42% | $163.5M | Benchmark Subject |
| VRXA Veraxa Biotech AG | D | 49/100 | — | — | — | -9.65% | $161.2M | /vrxa-vs-pepg → |
| ADAG Adagene Inc. | E | 25/100 | — | — | -35.0% | -8.76% | $165.8M | /adag-vs-pepg → |
| ANTX AN2 Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | -3.97% | $170.9M | /antx-vs-pepg → |
| ORMP Oramed Pharmaceuticals Inc. | E | 33/100 | — | 0.7% | -7.8% | -2.68% | $171.0M | /ormp-vs-pepg → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001835597 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), PepGen Inc. (PEPG) reported GAAP revenue of $262.1M (-4.2% vs. FY2024 revenue of $273.7M , and +10.4% cumulative change since FY2023) , GAAP net income of -$89.7M, operating cash flow of -$81.6M, and free cash flow of -$81.9M (+1.2% YoY). On the balance sheet, PEPG closed FY2025 with $173.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $262.1M | -$89.7M | -$81.6M | -$81.9M | $173.9M | — |
| FY2024 (FY) | 2024-12-31 | $273.7M | -$90.0M | -$82.4M | -$82.9M | $150.9M | — |
| FY2023 (FY) | 2023-12-31 | $237.3M | -$78.6M | -$69.0M | -$69.0M | — | — |
3. PEPG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PEPG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, PepGen Inc. (NASDAQ: PEPG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $2.35 (-0.42% 1D, market cap $163.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PEPG ranks #598 in composite RQD confidence.
How does PEPG compare to VRXA and ADAG in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PEPG carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VRXA (Veraxa Biotech AG) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $161.2M) and ADAG (Adagene Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $165.8M). Among the 5-stock peer group, PEPG leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PEPG?
Per PEPG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835597), PepGen Inc. generated $262.1M in revenue (-4.2% YoY), -$89.7M in net income, and -$81.9M in free cash flow against $173.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PEPG trading relative to its 50-day, 200-day, and 52-week technical levels?
PEPG last traded at $2.35 (-0.42% on volume of 565,921 shares), positioning the stock -13.60% below its 50-day simple moving average ($2.72) and -21.93% below its 200-day simple moving average ($3.01). Across its 52-week range of $1.31 to $7.80, PEPG sits at the 16.0% percentile with a 14-day RSI of 42.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.06 to $2.64).
ROARABLE RATING BRIEF • RQD 35/100 (D-)
✓ SEC XBRL & RQD VERIFIED
PEPG — PepGen Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
PepGen Inc. (PEPG) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.35 (-0.42% 1D, market capitalization $163.5M).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
PepGen Inc. (PEPG) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is — in each of the listed fiscal years, . Market capitalization is recorded as $166.9M in the market data and approximately $0.2B in the profile.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), PepGen Inc. (PEPG) reported $262.1M in annual revenue (up from $273.7M in FY2024, -4.2% YoY) and -$89.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($237.3M revenue, -$78.6M net income) through FY2025, PEPG scaled operating cash flow to -$81.6M and free cash flow to -$81.9M, backed by $173.9M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.31 – $7.80 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PEPG carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can PEPG sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $262.1M and free cash flow of -$81.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is PEPG's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
PEPG Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for PepGen Inc. (PEPG) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Seeking Alpha • 1d ago
PepGen: Maintaining 'Hold,' PGN-EDODM1 Data Is A Major Inflection Point Seeking Alpha report covering PepGen Inc. (PEPG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
PepGen Inc. Estimates – NASDAQ:PEPG TradingView report covering PepGen Inc. (PEPG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 1d ago
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and PepGen Inc. (PEPG) The Globe and Mail report covering PepGen Inc. (PEPG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 89d ago
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights BOSTON, August 06, 2026--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
🟡 MARKET WIRE Yahoo Finance • 89d ago
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review BOSTON, August 06, 2026--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
🟡 MARKET WIRE Yahoo Finance • 170d ago
Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now? PepGen Inc. (NASDAQ:PEPG) is one of the best NASDAQ stocks under $5 to buy right now. On May 12, PepGen reported Q1 2026 financial results, recording a net loss of $17.8 million, or $0.26 per share, compared to a net los
🟡 MARKET WIRE Yahoo Finance • 217d ago
PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway PepGen (NASDAQ:PEPG) reported top-line results from the lowest-dose cohort of its Phase II FREEDOM2 multiple ascending dose (MAD) study evaluating PGN-EDO-DM1 in myotonic dystrophy type 1 (DM1), highlighting what managem
🟢 CATALYST Yahoo Finance • 167d ago
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner PepGen (PEPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PEPG Bull vs. Bear Conversation Board — What's Your Call at $2.35?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PEPG 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH
🎯 Target: $2.93 (+24.2%)
📌 Pinned Debate PGN-EDODM1 data is flagged in the news wire as a major inflection point, and cash rose to $60.5M in FY 2025.
Here is why I am bullish on PEPG here at $2.36: PGN-EDODM1 data is flagged in the news wire as a major inflection point, and cash rose to $60.5M in FY 2025.. Compare PEPG's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $2.24 are getting bought.
CapAlloc_Nerd 🐂 BULL
@FadeTheHype Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH
🎯 Target: $1.82 (-22.9%)
Spot @ $2.36 ROIC of -35%, FCF of -$81.9M in FY 2025, and an RQD score of 38 indicate ongoing cash burn without revenue.
I respect the product at PepGen Inc., but the stock at $2.36 is a different story. ROIC of -35%, FCF of -$81.9M in FY 2025, and an RQD score of 38 indicate ongoing cash burn without revenue.. FCF yield is 0.0% and RQD sits at 35/100 (D-) — why pay up here when you can wait for next quarter's numbers?